Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06841055
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
- NCT06841055 ↗
- Recruiting
- BioNTech SE
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 25 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pumitamig; Docetaxel
- Arms
- Part 1A - Pumitamig Dose 1 + docetaxel · Experimental
- Part 1B - Pumitamig Dose 2 + docetaxel · Experimental
- Part 2: Selected doses of pumitamig + docetaxel · Experimental
- Enrollment
- 60 (estimated)
- Primary outcomes
- Part 1 - Occurrence of dose limiting toxicities (DLTs)
- Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest
- Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events
- Part 1 and Part 2 - Objective response rate
- Sponsor
- BioNTech SE with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- Start
- Mar 3, 2025
- Primary completion
- Oct 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06841055 · updated Apr 24, 2026